Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277103 | 0.84 | TSHR (0.35) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL4374381 | 0.81 | TSHR (0.44) | TSHRCYP3A4ATMTDP1RECQL | |
| Acrylic Acid SCHEMBL5062877 | 0.81 | TSHR (0.45) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL516622 | 0.81 | TSHR (0.66) | TSHRCYP3A4ATMTDP1RECQL | |
| Acrylic Acid SCHEMBL4419560 | 0.79 | TSHR (0.50) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL2275748 | 0.79 | TSHR (0.40) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL22081 | 0.78 | CA2 (0.47) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL20609791 | 0.78 | CA2 (0.47) | TSHRCYP3A4ATMTDP1RECQL | |
| SCHEMBL1283863 | 0.77 | TSHR (0.60) | TSHRCYP3A4ATMTDP1RECQL | |
| Vinyl Chloride SCHEMBL10826111 | 0.77 | TSHR (0.46) | TSHRCYP3A4ATMTDP1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989654-B2 | High purity bases of 3,3-diphenylpropylamino monoesters | UCB PHARMA GMBH (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20090012159-A1 | HIGH PURITY BASES OF 3,3-DIPHENYLPROPYLAMINO MONOESTERS | UCB PHARMA GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20060014832-A1 | Highly pure bases of 3,3-dipheyl propylamine monoesters | SCHWARZ PHARMA AG (DE) | 2006-01-19 | — | — | US | disclosed |
| US-20050226919-A1 | Device for transdermal administration for the treatment of urinary tract disorders | UCB PHARMA GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1293198-B1 | Device for transdermal administration for the treatment of urinary tract disorders | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003024432-A2 | DEVICE FOR TRANSDERMAL ADMINISTRATION FOR THE TREATMENT OF URINARY TRACT DISORDERS | SCHWARZ PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| EP-1293198-A1 | Device for transdermal administration for the treatment of urinary tract disorders | SCHWARZ PHARMA AG (DE) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014832-A1 | Highly pure bases of 3,3-dipheyl propylamine monoesters | ADRB3, DRD3, CYP3A5 | TSHR 567/4885CYP3A4 76/4885ATM 2823/4885 |
| US-20090012159-A1 | HIGH PURITY BASES OF 3,3-DIPHENYLPROPYLAMINO MONOESTERS | CYP11B2, CYP11B1, CYP21A2 | TSHR 474/4885CYP3A4 59/4885ATM 4110/4885 |
| US-20050226919-A1 | Device for transdermal administration for the treatment of urinary tract disorders | AR, CYP17A1, TACR1 | TSHR 465/4885CYP3A4 880/4885ATM 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.